US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
US5747469A
(en)
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
FR2688514A1
(en)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
|
DE69426841T2
(en)
|
1993-02-16 |
2001-09-06 |
Onyx Pharma Inc |
Cytopatic viruses for the therapy and prophylaxis of neoplasia
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
US7045347B2
(en)
|
1993-06-24 |
2006-05-16 |
Advec, Inc. |
Helper dependent adenovirus vectors based on integrase family site-specific recombinases
|
US20010006629A1
(en)
|
1993-10-25 |
2001-07-05 |
Richard J. Gregory |
Recombinant adenoviral vector and methods of use
|
US7252989B1
(en)
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5962311A
(en)
|
1994-09-08 |
1999-10-05 |
Genvec, Inc. |
Short-shafted adenoviral fiber and its use
|
US5965541A
(en)
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5559099A
(en)
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
FR2726285B1
(en)
|
1994-10-28 |
1996-11-29 |
Centre Nat Rech Scient |
ADENOVIRUSES CONTAINING VIABLE CONTAMINANT PARTICLES, PREPARATION AND USE
|
JPH10510987A
(en)
|
1994-12-12 |
1998-10-27 |
ジェネティック セラピー,インコーポレイテッド |
Improved adenovirus vectors and producer cells
|
US6127525A
(en)
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US5770442A
(en)
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US20030026789A1
(en)
|
1995-05-03 |
2003-02-06 |
Richard J. Gregory |
Gene therapy using replication competent targeted adenoviral vectors
|
US6506379B1
(en)
|
1995-06-07 |
2003-01-14 |
Ariad Gene Therapeutics, Inc. |
Intramuscular delivery of recombinant AAV
|
AUPN477695A0
(en)
|
1995-08-14 |
1995-09-07 |
Commonwealth Scientific And Industrial Research Organisation |
Gene therapy
|
US5945335A
(en)
*
|
1995-11-09 |
1999-08-31 |
Avigen, Inc. |
Adenovirus helper-free system for producing recombinant AAV virions lacking oncogenic sequences
|
US6083720A
(en)
|
1995-11-13 |
2000-07-04 |
Chroboczek; Jadwiga |
Dodecahedral adenoviral protein complex, composition containing same and uses thereof
|
EP1616961A1
(en)
|
1995-11-28 |
2006-01-18 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US6133243A
(en)
|
1996-02-22 |
2000-10-17 |
Onyx Pharmaceuticals, Inc. |
Liposomal-viral DNA complexes for treating disease
|
FR2746110B1
(en)
|
1996-03-14 |
1998-04-17 |
|
METHOD OF TREATING GENE THERAPY OF HUMAN TUMORS AND CORRESPONDING RECOMBINANT VIRUSES
|
US6506602B1
(en)
|
1996-03-25 |
2003-01-14 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
CA2258158A1
(en)
|
1996-07-01 |
1998-01-08 |
Francis Blanche |
Method for producing recombinant adenovirus
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
US5922315A
(en)
|
1997-01-24 |
1999-07-13 |
Genetic Therapy, Inc. |
Adenoviruses having altered hexon proteins
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
US20050287120A1
(en)
|
1997-03-21 |
2005-12-29 |
Fisher Paul B |
Cancer - targeted viral vectors
|
FR2761689B1
(en)
|
1997-04-02 |
1999-06-25 |
Transgene Sa |
MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS
|
CA2291323A1
(en)
|
1997-05-28 |
1998-12-03 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US6200799B1
(en)
|
1997-06-03 |
2001-03-13 |
University Of Lausanne |
Somatic gene therapy to suppress secondary cataract formation following eye surgery
|
DE69820450T2
(en)
|
1997-06-09 |
2004-05-27 |
Genvec, Inc. |
CHIMEAR VECTORS CONTAINING THE PACKAGING REGION OF A PHAGE GENENOM AND PART OF THE GENOME OF AN EUKARYONTIC VIRUS
|
EP1044280A1
(en)
|
1997-12-12 |
2000-10-18 |
Onyx Pharmaceuticals, Inc. |
SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS
|
US7297542B2
(en)
|
1998-02-06 |
2007-11-20 |
The Uab Research Foundation |
Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
CA2321135A1
(en)
|
1998-02-17 |
1999-08-19 |
Uab Research Foundation |
Modified adenovirus containing a fiber replacement protein
|
US20050095231A1
(en)
|
1998-02-17 |
2005-05-05 |
Curiel David T. |
Modified adenovirus containing a fiber replacement protein
|
AU2796799A
(en)
|
1998-03-03 |
1999-09-20 |
Uab Research Foundation, The |
Amplification of gene transfer and gene therapy by controlled replication
|
AU3358999A
(en)
|
1998-03-20 |
1999-10-11 |
Genzyme Corporation |
Chimeric adenoviral vectors for targeted gene delivery
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US7829329B2
(en)
|
1998-04-24 |
2010-11-09 |
Onyx Pharmaceuticals, Inc. |
Adenoviral vectors for treating disease
|
PT1199368E
(en)
|
1998-07-07 |
2004-04-30 |
Transgene Sa |
USING ADENOVIRAL REGION E4 BLOCKS TO IMPROVE EXPRESSION OF A RELEVANT GENE
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
JP2002523105A
(en)
|
1998-08-27 |
2002-07-30 |
アバンテイス・フアルマ・エス・アー |
Targeted adenovirus vectors for delivery of heterologous genes
|
US6900049B2
(en)
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
CA2342396A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US6841540B1
(en)
|
1998-09-29 |
2005-01-11 |
The Uab Research Foundation |
Immunomodulation by genetic modification of dendritic cells and B cells
|
CZ301506B6
(en)
|
1998-10-15 |
2010-03-31 |
Canji, Inc. |
Selectively replicating viral vectors and process of its preparation, pharmaceutical formulation, method of killing a cell having defective pathway, transformed cell and promoter responsive to p53 and TGF-{beta} pathways
|
US20020037274A1
(en)
|
1998-10-26 |
2002-03-28 |
Angelica Williams |
Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
AU772630B2
(en)
|
1999-01-14 |
2004-05-06 |
Novartis Ag |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
US6395875B1
(en)
|
1999-01-25 |
2002-05-28 |
Brookhaven Science Associates Llc |
Recombinant soluble adenovirus receptor
|
US7157266B2
(en)
|
1999-01-25 |
2007-01-02 |
Brookhaven Science Associates Llc |
Structure of adenovirus bound to cellular receptor car
|
WO2000052186A1
(en)
|
1999-03-04 |
2000-09-08 |
Introgene B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
AU767904B2
(en)
|
1999-05-12 |
2003-11-27 |
Uab Research Foundation, The |
Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
|
US20040175362A1
(en)
|
1999-05-12 |
2004-09-09 |
Curiel David T. |
Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
|
AU777041B2
(en)
|
1999-05-17 |
2004-09-30 |
Crucell Holland B.V. |
Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
|
US20050232900A1
(en)
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US7094398B1
(en)
|
1999-06-01 |
2006-08-22 |
University Of Washington |
Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
|
AU5464000A
(en)
|
1999-06-01 |
2000-12-18 |
University Of Washington |
Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
|
EP1593742A3
(en)
|
1999-06-01 |
2006-02-01 |
The University of Washington |
Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
|
DE19929569A1
(en)
|
1999-06-21 |
2000-12-28 |
Holm Per Sonne |
Composition for treating malignant disease, comprising E1A-defective adenovirus that can replicate in presence of YB-1 protein
|
CN1359391A
(en)
|
1999-07-06 |
2002-07-17 |
哥德-A-基因股份公司 |
Recombinant adenovirus
|
US7589069B1
(en)
|
1999-07-12 |
2009-09-15 |
Saint Louis University |
Replication-competent anti-cancer vectors
|
EP1124977A1
(en)
|
1999-08-27 |
2001-08-22 |
Transgene S.A. |
Modified adenoviral fibre and uses thereof
|
AU1070901A
(en)
|
1999-09-23 |
2001-04-24 |
Genvec, Inc. |
Method of treating cells of the prostate prophylactically or therapeutically
|
AU773019B2
(en)
|
1999-09-24 |
2004-05-13 |
Uab Research Foundation, The |
Capsid-modified recombinant adenovirus and methods of use
|
WO2001023004A1
(en)
|
1999-09-30 |
2001-04-05 |
The Trustees Of The University Of Pennsylvania |
Replication selective adenoviruses for use in cancer therapy
|
AU1087701A
(en)
|
1999-10-15 |
2001-04-30 |
Canji, Inc. |
Targeted vectors
|
CA2388807C
(en)
|
1999-11-12 |
2013-08-06 |
Matthew C. Coffey |
Viruses for the treatment of cellular proliferative disorders
|
DK1230378T3
(en)
|
1999-11-15 |
2007-10-08 |
Onyx Pharma Inc |
An oncolytic adenovirus
|
US6867022B1
(en)
|
2000-01-21 |
2005-03-15 |
Regents Of The University Of Michigan |
Replication deficient adenovirus vectors and methods of making and using them
|
WO2001058940A2
(en)
|
2000-02-09 |
2001-08-16 |
Genvec, Inc. |
Adenoviral capsid containing chimeric protein ix
|
US6692736B2
(en)
|
2000-03-24 |
2004-02-17 |
Cell Genesys, Inc. |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
AU4764801A
(en)
|
2000-03-24 |
2001-10-08 |
Calydon Inc |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
US6911200B2
(en)
|
2000-03-24 |
2005-06-28 |
Cell Genesys, Inc. |
Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
|
US20030082146A1
(en)
|
2000-04-26 |
2003-05-01 |
Van Es Helmuth H. G. |
Adenovirus vectors with knobless fibers, and their uses
|
CA2407881A1
(en)
|
2000-05-01 |
2001-11-08 |
Novartis Ag |
Vectors for ocular transduction and use thereof for genetic therapy
|
US7332337B2
(en)
|
2000-05-16 |
2008-02-19 |
Galapagos Nv |
Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
|
EP1157999A1
(en)
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
JP4744771B2
(en)
|
2000-05-26 |
2011-08-10 |
大日本住友製薬株式会社 |
Novel recombinant adenovirus vector with reduced side effects
|
EP1301612A2
(en)
|
2000-05-31 |
2003-04-16 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
EP1285079A2
(en)
|
2000-05-31 |
2003-02-26 |
University of Saskatchewan |
Modified bovine adenovirus having altered tropism
|
US7754201B2
(en)
|
2000-06-02 |
2010-07-13 |
GenPhar, Inc |
Method of vaccination through serotype rotation
|
EP1167533A1
(en)
|
2000-06-23 |
2002-01-02 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Methods and means for the complementation of viral protein expression in stable cell lines
|
US6579522B1
(en)
|
2000-06-27 |
2003-06-17 |
Genvec, Inc. |
Replication deficient adenoviral TNF vector
|
US20020106382A1
(en)
|
2000-07-14 |
2002-08-08 |
Young Charles S.H. |
Modified adenovirus and uses thereof
|
US7022496B2
(en)
|
2000-07-14 |
2006-04-04 |
The Johns Hopkins University |
Use of gene product of adenovirus early region 4 ORF-6 to inhibit repair of double-strand breaks in DNA
|
GB0017720D0
(en)
|
2000-07-19 |
2000-09-06 |
Got A Gene Ab |
Modified virus
|
ATE315095T1
(en)
|
2000-08-10 |
2006-02-15 |
Crucell Holland Bv |
ADENOVIRUS VECTORS FOR TRANSDUCTION OF CHONDROCYTES
|
US7235233B2
(en)
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
CA2430947A1
(en)
|
2000-12-08 |
2002-06-13 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US20030095989A1
(en)
|
2000-12-18 |
2003-05-22 |
Irving John M. |
Chimeric cytolytic viruses for cancer treatment
|
US6635466B2
(en)
|
2001-01-09 |
2003-10-21 |
University Of Iowa Research Foundation |
Adenovirus serotype 30 (Ad30)
|
AU2002250081A1
(en)
|
2001-02-14 |
2002-08-28 |
Uab Research Foundation |
Combined transductional and transcriptional targeting system for improved gene delivery
|
IL152420A0
(en)
|
2001-02-23 |
2003-05-29 |
Novartis Ag |
Novel oncolytic adenoviral vectors
|
WO2002079507A2
(en)
|
2001-04-02 |
2002-10-10 |
Bayer Aktiengesellschaft |
Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
|
US20030219899A1
(en)
|
2001-04-17 |
2003-11-27 |
Nikolay Korokhov |
Mosaic adenoviral vectors
|
US20030138405A1
(en)
*
|
2001-04-17 |
2003-07-24 |
Juan Fueyo |
Conditionally replicative adenovirus to target the Rb and Rb-related pathways
|
WO2002083880A1
(en)
|
2001-04-17 |
2002-10-24 |
Vectorlogics, Inc. |
Mosaic adenoviral vectors
|
ATE530672T1
(en)
|
2001-06-22 |
2011-11-15 |
Univ Pennsylvania |
RECOMBINANT ADENOVIRUSES WITH MONKEY ADENOVIRUS PROTEINS AND USE THEREOF.
|
US6844192B2
(en)
*
|
2001-06-29 |
2005-01-18 |
Wake Forest University |
Adenovirus E4 protein variants for virus production
|
US6905678B2
(en)
|
2001-07-07 |
2005-06-14 |
Crucell Holland B.V. |
Gene delivery vectors with cell type specificity for mesenchymal stem cells
|
US20030021768A1
(en)
|
2001-07-23 |
2003-01-30 |
Yuqiao Shen |
Viral mutants that selectively replicate in targeted human cancer cells
|
US6838285B2
(en)
|
2001-09-18 |
2005-01-04 |
Becton Dickinson |
Site specific recombinase based method for producing adenoviral vectors
|
US7569217B2
(en)
*
|
2001-09-24 |
2009-08-04 |
University Of Saskatchewan |
Porcine adenovirus E1 and E4 regions
|
EP1446479B1
(en)
|
2001-09-29 |
2012-08-15 |
Chae-Ok Yun |
Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
|
BR0214350A
(en)
|
2001-11-21 |
2005-05-10 |
Univ Pennsylvania |
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same and methods of use
|
CN100475966C
(en)
|
2001-11-23 |
2009-04-08 |
上海三维生物技术有限公司 |
New-type adenovirus with tumor cell specific infection and transgenic expression capability
|
EP1327688A1
(en)
|
2002-01-14 |
2003-07-16 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
Adenoviruses with enhanced lytic potency
|
CA2474763A1
(en)
|
2002-01-24 |
2003-07-31 |
The Scripps Research Institute |
Fiber shaft modifications for efficient targeting
|
EP1470233A1
(en)
|
2002-02-01 |
2004-10-27 |
Transgene S.A. |
Adenoviral vectors for modulating the cellular activities associated with pods
|
US20030220284A1
(en)
|
2002-02-22 |
2003-11-27 |
Patricia Yotnda |
Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
|
US20040005710A1
(en)
|
2002-03-09 |
2004-01-08 |
Ho-Sun Son |
Method for producing recombinant viruses using site-specific recombination
|
JP2005526099A
(en)
|
2002-03-26 |
2005-09-02 |
オンコリティクス バイオテック, インコーポレイティッド |
Use of adenovirus with mutated VA gene for cancer treatment
|
JP4495587B2
(en)
*
|
2002-04-25 |
2010-07-07 |
クルセル ホランド ベー ヴェー |
Recombinant adenovirus vector and use thereof
|
EP1499332A4
(en)
|
2002-04-29 |
2006-12-06 |
Hadasit Med Res Service |
Compositions and methods for treating cancer with an oncolytic viral agent
|
EP1504016A4
(en)
|
2002-05-08 |
2006-11-22 |
Intronn Inc |
Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
|
KR101083450B1
(en)
|
2002-05-27 |
2011-11-16 |
페르 손네 홀름 |
Novel use of adenoviruses and nucleic acids coding therefor
|
JP2006514538A
(en)
|
2002-07-10 |
2006-05-11 |
トランスジーン ソシエテ アノニム |
Modified adenovirus fibers with removed binding to cellular receptors
|
AU2003253992A1
(en)
|
2002-07-18 |
2004-02-09 |
Robert P. Bennett |
Viral vectors containing recombination sites
|
US7364727B2
(en)
|
2002-07-22 |
2008-04-29 |
Cell Genesys, Inc. |
Metastatic colon cancer specific promoter and uses thereof
|
EP1539937A4
(en)
*
|
2002-08-22 |
2006-07-26 |
Merck & Co Inc |
Methods for propagating adenovirus and virus produced thereby
|
CN1720066B
(en)
|
2002-10-01 |
2012-05-23 |
杜克大学 |
Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
|
EP1413586A1
(en)
|
2002-10-21 |
2004-04-28 |
Centre National De La Recherche Scientifique (Cnrs) |
Regulation of the Cre recombinase using a dissociation/re-association system of said recombinase
|
US20040102382A1
(en)
|
2002-11-27 |
2004-05-27 |
Transgene, S.A. |
Targeting peptides
|
WO2004083418A1
(en)
|
2003-03-17 |
2004-09-30 |
Merck & Co., Inc. |
Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
|
US20040191761A1
(en)
|
2003-03-27 |
2004-09-30 |
Routes John M. |
Modified adenoviral E1A constructs and methods of use thereof
|
CA2519207A1
(en)
|
2003-03-28 |
2004-11-11 |
Merck & Co., Inc. |
Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
|
CA2519680A1
(en)
|
2003-03-28 |
2004-11-18 |
The Scripps Research Institute |
Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
|
US20040213764A1
(en)
|
2003-03-28 |
2004-10-28 |
William Wold |
Adenovirus replication-competent vectors expressing trail
|
US20050095705A1
(en)
|
2003-04-15 |
2005-05-05 |
Michael Kadan |
Method for production of oncolytic adenoviruses
|
US20060281090A1
(en)
|
2003-05-01 |
2006-12-14 |
University Of Washington Uw Tech Transfer- Invention Licensing |
Capsid-modified adenovirus vectors and methods of using the same
|
WO2004101799A2
(en)
|
2003-05-14 |
2004-11-25 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Broadening adenovirus tropism
|
US20050079158A1
(en)
|
2003-06-05 |
2005-04-14 |
Shenzhen Allucks Biotech Co., Ltd. |
Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof
|
CA2527721C
(en)
|
2003-06-10 |
2016-05-10 |
University Of Saskatchewan |
Chimeric adenovirus capsid proteins
|
JP2007531507A
(en)
|
2003-06-11 |
2007-11-08 |
ザ スクリップス リサーチ インスティテュート |
Modified fiber protein for efficient receptor binding
|
ES2478625T3
(en)
|
2003-06-20 |
2014-07-22 |
The Trustees Of The University Of Pennsylvania |
Method of generating chimeric adenoviruses and uses of such chimeric adenoviruses
|
US7291498B2
(en)
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
US20050036989A1
(en)
|
2003-07-18 |
2005-02-17 |
Onyx Pharmaceuticals, Inc. |
Subgroup B adenoviral vectors for treating disease
|
ES2391975T3
(en)
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Adenoviral vector based vaccines
|
US20050186178A1
(en)
|
2003-08-28 |
2005-08-25 |
Ennist David L. |
Oncolytic adenoviral vectors encoding GM-CSF
|
AU2003265873A1
(en)
|
2003-08-28 |
2005-04-14 |
Cell Genesys, Inc. |
Oncolytic adenoviral vectors encoding gm-csf
|
EP1664099A2
(en)
|
2003-09-09 |
2006-06-07 |
Niels Rudi Pedersen |
Adenoviral epitopes
|
US7482156B2
(en)
|
2003-10-15 |
2009-01-27 |
Cell Genesys, Inc. |
Hepatocellular carcinoma specific promoter and uses thereof
|
CA2546178A1
(en)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
New use of adenovirus and nucleic acids coding therefor
|
US20050201978A1
(en)
|
2003-11-17 |
2005-09-15 |
Lipton James S. |
Tumor and infectious disease therapeutic compositions
|
EP1702071B1
(en)
|
2003-12-31 |
2012-02-22 |
Kalobios Inc. |
Transactivation system for mammalian cells
|
WO2005075506A1
(en)
|
2004-01-09 |
2005-08-18 |
The Scripps Research Institute |
Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
|
CN107723298A
(en)
|
2004-01-23 |
2018-02-23 |
Msd意大利有限公司 |
Chimpanzee adenovirus vaccine carriers
|
US20050201936A1
(en)
|
2004-02-12 |
2005-09-15 |
Wold William S.M. |
Models for viral-based cancer therapy
|
WO2005086922A2
(en)
|
2004-03-10 |
2005-09-22 |
Board Of Regents, University Of Texas System |
Oncolytic adenovirus armed with therapeutic genes
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
WO2006075819A1
(en)
|
2004-03-30 |
2006-07-20 |
Industry-Academic Cooperation Foundation, Yonsei University |
Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
|
US20080292592A1
(en)
|
2004-04-30 |
2008-11-27 |
Sunil Chada |
Oncolytic Adenovirus Armed with Therapeutic Genes
|
EP1743041B1
(en)
|
2004-05-03 |
2012-06-27 |
Stefan Kochanek |
Modified viral vector particles
|
GB0411428D0
(en)
|
2004-05-21 |
2004-06-23 |
Got A Gene Ab |
Vectors
|
ATE491799T1
(en)
|
2004-05-26 |
2011-01-15 |
Bayer Schering Pharma Ag |
CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT
|
US20050271622A1
(en)
|
2004-06-03 |
2005-12-08 |
Shenzhen Allucks Biotech Co., Ltd. |
Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
|
WO2005117993A2
(en)
|
2004-06-04 |
2005-12-15 |
Genvec, Inc. |
Method of using adenoviral vectors with improved safety and efficacy for the treatment of cancer
|
CN100361710C
(en)
|
2004-06-07 |
2008-01-16 |
成都康弘生物科技有限公司 |
Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
|
US20060292682A1
(en)
|
2004-07-22 |
2006-12-28 |
Hawkins Lynda K |
Addition of transgenes into adenoviral vectors
|
GB0416487D0
(en)
|
2004-07-23 |
2004-08-25 |
Isis Innovation |
Modified virus
|
US7776322B2
(en)
|
2004-08-16 |
2010-08-17 |
Stefan Kochanek |
Modified viral vector particles
|
EP1784493A2
(en)
|
2004-09-01 |
2007-05-16 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
US7943373B2
(en)
|
2004-09-29 |
2011-05-17 |
Oncolys Biopharma, Inc. |
Telomelysin/GFP-expressing recombinant virus
|
AP2351A
(en)
|
2004-10-13 |
2012-01-25 |
Crucell Holland Bv |
Improved adenoviral vectors and uses thereof.
|
BRPI0517021A
(en)
|
2004-10-25 |
2008-09-30 |
Novartis Ag |
tor polynucleotides and polypeptides, and methods of use
|
IL166049A0
(en)
|
2004-12-30 |
2006-01-15 |
Gavish Galilee Bio Appl Ltd |
Method for obtaining modified proteins and viruseswith intact native binding
|
US20090232800A1
(en)
|
2004-12-31 |
2009-09-17 |
Per Sonne Holm |
E1-minus adenoviruses and use thereof
|
KR101527213B1
(en)
|
2004-12-31 |
2015-06-09 |
페르 손네 홀름 |
Method for reversing multiple resistance in animal cells
|
WO2006086357A2
(en)
|
2005-02-10 |
2006-08-17 |
Merck & Co., Inc. |
Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
|
JP2008538894A
(en)
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
Adenovirus serotype 26 vector, nucleic acid and virus produced thereby
|
KR100747646B1
(en)
|
2005-02-25 |
2007-08-08 |
연세대학교 산학협력단 |
Gene Delivery System Containing Decorin Gene and Pharmaceutical Composition for Treating Cancer containing the System
|
WO2006119449A2
(en)
|
2005-05-04 |
2006-11-09 |
Vectorlogics, Inc. |
Modified adenovirus containing a stabilized antibody
|
WO2007050128A2
(en)
|
2005-05-31 |
2007-05-03 |
Vectorlogics, Inc. |
Shielded adenoviral vectors and methods of use
|
ES2948791T3
(en)
|
2005-06-17 |
2023-09-19 |
Msd Italia Srl |
Hepatitis C virus nucleic acid vaccine
|
WO2007027860A2
(en)
|
2005-08-31 |
2007-03-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
KR100723009B1
(en)
|
2005-11-30 |
2007-05-29 |
한국원자력연구원 |
A pharmaceutical composition for treating malignant tumors containing human p31 genes
|
ES2304281B1
(en)
|
2006-02-01 |
2009-08-12 |
Dnatrix Inc. |
ADENOVIRUS ONCOLITICOS FOR THE TREATMENT OF CANCER.
|
WO2007094653A1
(en)
|
2006-02-13 |
2007-08-23 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg |
Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
|
WO2007103825A2
(en)
|
2006-03-02 |
2007-09-13 |
The Board Of Regents Of The University Of Texas System |
Combination therapy with oncolytic adenovirus
|
US20070292954A1
(en)
|
2006-04-21 |
2007-12-20 |
The Brigham And Women's Hospital, Inc. |
Generation of recombinant DNA by sequence-and ligation-independent cloning
|
WO2008010864A2
(en)
|
2006-04-28 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
Modified adenovirus hexon protein and uses thereof
|
US20080242608A1
(en)
|
2006-06-02 |
2008-10-02 |
Azad Bonni |
Methods and compositions for treating and preventing neurologic disorders
|
EP2041291A1
(en)
|
2006-06-19 |
2009-04-01 |
Institut Gustave Roussy |
Inhibition of the liver tropism of adenoviral vectors
|
JP2008048621A
(en)
|
2006-08-22 |
2008-03-06 |
Chiba Prefecture |
Method for creating chimeric adenovirus and pharmaceutical using the same
|
GR20060100496A
(en)
|
2006-09-01 |
2008-04-15 |
Παρθενιος Μπουλικας |
LIPOSOMALLY ENCAPSULATED HYBRID ADENOVIRUS-SEMLIKI FOREST VIRUS (SFV) VECTORS CARRYING RNAi CONSTRUCTS AND THERAPEUTIC GENES FOR USE AGAINST CANCER TARGETS AND OTHER DISEASES.
|
US20100098668A1
(en)
|
2006-09-29 |
2010-04-22 |
Northshore University Health System |
Oncolytic Adenoviruses and Uses Thereof
|
US20100272753A1
(en)
|
2006-10-26 |
2010-10-28 |
The Johns Hopkins University |
Recombinant Adenovirus Vaccines
|
ES2422299T3
(en)
|
2006-11-28 |
2013-09-10 |
Nerviano Medical Sciences Srl |
Indocyls (4,5-dihydro) tricyclic indoles
|
WO2008095168A2
(en)
|
2007-02-01 |
2008-08-07 |
University Of Chicago |
Compositions and methods related to a recombinant adenoviral vector that targets il 13 receptors
|
CN101702918B
(en)
|
2007-03-14 |
2013-03-27 |
卡塔拉肿瘤研究所 |
Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and use in cancer treatment thereof
|
US20090081639A1
(en)
|
2007-05-31 |
2009-03-26 |
Phil Hill |
Assay for sensitivity to chemotherapeutic agents
|
WO2009065800A1
(en)
|
2007-11-20 |
2009-05-28 |
Crucell Holland B.V. |
Recombinant human adenoviruses for eliciting mucosal immune responses
|
CA2706258C
(en)
|
2007-11-28 |
2017-06-06 |
The Trustees Of The University Of Pennsylvania |
Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
|
DK2220242T3
(en)
|
2007-11-28 |
2017-03-27 |
Univ Pennsylvania |
ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF
|
EP2463362B1
(en)
|
2007-11-28 |
2017-11-08 |
The Trustees Of The University Of Pennsylvania |
Simian subfamily c adenovirus SAdv-31 and uses thereof
|
US20110104788A1
(en)
|
2008-02-07 |
2011-05-05 |
Andrew Baker |
Modulation of Adenoviral Tropism
|
JP5661476B2
(en)
|
2008-03-04 |
2015-01-28 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Simian adenovirus SAdV-36, -42.1, -42.2 and -44 and their uses
|
WO2009117656A2
(en)
|
2008-03-21 |
2009-09-24 |
Vectorlogics,Inc. |
Capsid-incorporated antigen for novel adenovirus vaccine
|
US20110086063A1
(en)
|
2008-06-04 |
2011-04-14 |
Cornell University |
Vaccines for prevention and treatment of addiction
|
BRPI0914223A2
(en)
|
2008-06-19 |
2019-09-24 |
Millennium Pharm Inc |
thiophene or thiazole derivatives and their uses as p13k inhibitors
|
KR101034811B1
(en)
|
2008-08-25 |
2011-05-16 |
단국대학교 산학협력단 |
Recombinant adenovirus comprising tissu-specific promoter and tumor-targeting trans-splicing ribozyme and uses thereof
|
KR20110081222A
(en)
|
2008-09-26 |
2011-07-13 |
어번 유니버시티 |
Immunization of avians by mucosal administration of non-replicating vectored vaccines
|
EP2774985B1
(en)
|
2008-10-31 |
2016-12-14 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus SAdV-43 and uses thereof
|
ES2612889T3
(en)
|
2008-12-22 |
2017-05-19 |
Targovax Oy |
Oncolytic adenoviral vectors and related procedures and uses
|
US9345787B2
(en)
|
2008-12-22 |
2016-05-24 |
Targovax Oy |
Adenoviral vectors and methods and uses related thereto
|
KR101763093B1
(en)
|
2009-02-02 |
2017-07-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Simian Adenovirus Nucleic Acid- and Amino Acid-Sequences, Vectors Containing Same, and Uses Thereof
|
ES2750305T3
(en)
|
2009-03-02 |
2020-03-25 |
Univ California |
E1A and E1B mutants of tumor-selective adenoviruses
|
ES2385251B1
(en)
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
ONCOLYTIC ADENOVIRUSES FOR THE TREATMENT OF CANCER.
|
WO2010138675A1
(en)
|
2009-05-29 |
2010-12-02 |
The Trustees Of The University Of Pennsylvania |
Simian adenovirus 41 and uses thereof
|
KR20120052369A
(en)
|
2009-07-31 |
2012-05-23 |
팍스박스, 인코포레이티드 |
Adenoviral-based vectors
|
US9555089B2
(en)
|
2009-08-18 |
2017-01-31 |
The Rockefeller University |
Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
|
WO2011022002A1
(en)
|
2009-08-18 |
2011-02-24 |
The Rockefeller University |
Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
|
KR101248912B1
(en)
|
2009-12-31 |
2013-03-29 |
한양대학교 산학협력단 |
Recombinant Adenovirus Having Anti―Angiogenesis Activity
|
WO2011101869A1
(en)
|
2010-02-22 |
2011-08-25 |
Transgene Biotek Ltd. |
Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer
|
CN102191245B
(en)
|
2010-03-15 |
2013-11-13 |
浙江东方基因生物制品有限公司 |
Method and reagent for detecting tumor cell in circulatory blood by applying tumor peculiar promoter to express reporter gene
|
US9682133B2
(en)
|
2010-03-17 |
2017-06-20 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
US20130058897A1
(en)
|
2010-04-14 |
2013-03-07 |
Mogam Biotechnology Research Institute |
Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
|
WO2011133040A2
(en)
|
2010-04-23 |
2011-10-27 |
Orca Therapeutics B.V. |
Replication-competent adenoviruses
|
US9018182B2
(en)
|
2010-04-26 |
2015-04-28 |
Green Cross Corporation |
Tumor specific promoter and oncolytic virus vector comprising the same
|
EP2580234B1
(en)
|
2010-06-10 |
2017-03-08 |
University Of Washington Through Its Center For Commercialization |
Methods and systems for adenovirus interaction with desmoglein 2 (dsg2)
|
WO2012003287A2
(en)
|
2010-06-30 |
2012-01-05 |
The Johns Hopkins University |
Compositions and methods for detecting and quantifying circulating tumor cells ctcs
|
WO2012024350A2
(en)
|
2010-08-16 |
2012-02-23 |
Salk Institute For Biological Studies |
Anti-cancer adenoviruses
|
WO2012024351A2
(en)
|
2010-08-16 |
2012-02-23 |
Salk Institute For Biological Studies |
Adenoviral assembly method
|
WO2012022496A2
(en)
|
2010-08-19 |
2012-02-23 |
Per Sonne Holm |
Method for killing tumor stem cells
|
BR112013006699A2
(en)
|
2010-09-24 |
2016-06-14 |
Oncos Therapeutics Oy |
oncolytic adenoviral vector encoding monoclonal anti-ct4-4 antibodies, cell and pharmaceutical composition comprising the same, method of producing ctla-4 specific human monoclonal antibody in a cell and use of said adenoviral vector
|
JP2013541945A
(en)
|
2010-09-24 |
2013-11-21 |
オンコス セラピュティックス オサケ ユキチュア |
Oncolytic adenoviral vectors and related methods and uses
|
AU2011332025B2
(en)
|
2010-11-23 |
2015-06-25 |
The Trustees Of The University Of Pennsylvania |
Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
CN102174479B
(en)
|
2011-03-02 |
2013-04-03 |
北京锤特生物科技有限公司 |
Oncolytic virus for targeted treatment of human tumors and application thereof
|
WO2012132369A1
(en)
|
2011-03-25 |
2012-10-04 |
国立大学法人鹿児島大学 |
Viral vector targeting cancer stem cells
|
WO2012156933A1
(en)
|
2011-05-16 |
2012-11-22 |
Institut Gustave Roussy |
Combination of oncolytic adenoviruses with histone deacetylase inhibitors
|
WO2012162342A2
(en)
|
2011-05-23 |
2012-11-29 |
The Wistar Institute Of Anatomy And Biology |
Influenza vaccines containing modified adenovirus vectors
|
GB201108879D0
(en)
|
2011-05-25 |
2011-07-06 |
Isis Innovation |
Vector
|
CN102260712B
(en)
|
2011-05-31 |
2013-10-02 |
北京锤特生物科技有限公司 |
Construction and application of type B adenovirus hominis Ad11 mutant with enhanced tumor dissolving ability
|
KR101946666B1
(en)
|
2011-08-23 |
2019-02-11 |
고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 |
Conditionally replication-competent adenovirus
|
WO2013036791A2
(en)
|
2011-09-09 |
2013-03-14 |
Beth Israel Deaconess Medical Center, Inc. |
Modified adenoviral vectors and methods of treatment using same
|
JP6757120B2
(en)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
Afen adenovirus (gorilla) or adenovirus vector, and how to use
|
FI123955B
(en)
|
2011-11-25 |
2014-01-15 |
Oncos Therapeutics Ltd |
Oncolytic adenovirus
|
US9267153B2
(en)
|
2011-12-15 |
2016-02-23 |
Washington University |
Porcine knob xenotype chimeric adenoviral vector for dendritic cell infection
|
CA2863523A1
(en)
|
2012-02-02 |
2013-08-08 |
Juan FUEYO-MARGARETO |
Recombinant adenovirus expressing cancer antigens
|
SI2825640T1
(en)
|
2012-03-12 |
2016-08-31 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
EP2825649B1
(en)
|
2012-03-13 |
2019-07-31 |
The Salk Institute for Biological Studies |
Selective cell targeting using adenovirus and chemical dimers
|
CN107267554A
(en)
|
2012-03-14 |
2017-10-20 |
萨克生物研究学院 |
Adenovirus diagnosing tumor method
|
US9017672B2
(en)
|
2012-05-11 |
2015-04-28 |
Immunicum Aktiebolag |
Hexon Tat-PTD modified adenovirus and uses thereof
|
CN105473723A
(en)
|
2012-05-18 |
2016-04-06 |
宾夕法尼亚大学托管会 |
Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
|
US9476061B2
(en)
|
2012-05-24 |
2016-10-25 |
Janssen Vaccines & Prevention B.V. |
Adenoviral vectors for transduction of vascular tissue
|
EP2855669B1
(en)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modified serotype 28 adenoviral vectors
|
AU2013203696A1
(en)
|
2012-06-25 |
2014-01-16 |
University Of Canberra |
Recombinant Viral Vectors and Uses Therefor
|
US20150246949A1
(en)
|
2012-09-25 |
2015-09-03 |
University Of Washington Through Its Center For Commercialization |
Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor
|
KR101429696B1
(en)
|
2012-11-21 |
2014-08-13 |
국립암센터 |
Recombinant adenovirus with enhanced safety and anti-cancer activity and use thereof
|
CN105189739A
(en)
|
2013-02-28 |
2015-12-23 |
普赛奥克苏斯治疗公司 |
A process for the production of adenovirus
|
WO2014160475A1
(en)
|
2013-03-13 |
2014-10-02 |
Aboody Karen S |
Tropic cell based virotherapy for the treatment of cancer
|
EP2971008B1
(en)
|
2013-03-14 |
2018-07-25 |
Salk Institute for Biological Studies |
Oncolytic adenovirus compositions
|
AU2014255733B2
(en)
|
2013-04-18 |
2019-05-16 |
Tilt Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
RU2689553C2
(en)
|
2013-06-18 |
2019-05-28 |
Днатрикс, Инк. |
Cerebral cancer treatment with oncolytic adenovirus
|
BR112016006564B1
(en)
|
2013-09-24 |
2023-11-21 |
University Of Washington Through Its Center For Commercialization |
RECOMBINANT ADB-2/3 FIBER POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION
|
SG10201907841UA
(en)
|
2013-11-22 |
2019-10-30 |
Dnatrix Inc |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
GB201415579D0
(en)
|
2014-09-03 |
2014-10-15 |
Psioxus Therapeutics Ltd |
A process
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
EP2940128A1
(en)
|
2014-04-30 |
2015-11-04 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Adenovirus comprising an albumin-binding moiety
|
ES2714921T3
(en)
|
2014-05-19 |
2019-05-30 |
Valo Therapeutics Oy |
Coated oncolytic adenovirus for cancer vaccines
|
CN106459930B
(en)
|
2014-05-28 |
2020-03-03 |
国立大学法人冈山大学 |
Conditionally replicating adenovirus expressing REIC gene
|
CA2961748A1
(en)
|
2014-09-24 |
2016-03-31 |
Salk Institute For Biological Studies |
Oncolytic tumor viruses and methods of use
|
US10617729B2
(en)
|
2014-12-24 |
2020-04-14 |
The Uab Research Foundation |
Multitargeting onocolytic adenovirus, methods of use, and methods of making
|
EP3247807B1
(en)
|
2015-01-20 |
2020-12-16 |
Adcure Biotechnologies, LLC. |
Detargeted adenovirus variants and related methods
|
US20180051301A1
(en)
|
2015-03-02 |
2018-02-22 |
Washington University |
Induction of pacemaker-like cells from cardiomyocytes
|
JP6754532B2
(en)
|
2015-03-17 |
2020-09-16 |
ティーアイエルティー・バイオセラピューティクス・オーワイTILT Biotherapeutics Oy |
Oncolytic adenovirus encoding bispecific antibodies and related methods and uses
|
EP3072900A1
(en)
|
2015-03-27 |
2016-09-28 |
Medizinische Hochschule Hannover |
Anti-tumour medicament based on adenovirus
|
GB201505860D0
(en)
|
2015-04-07 |
2015-05-20 |
Agalimmune Ltd |
Therapeutic compositions and methods of use for treating cancer
|
GB201513176D0
(en)
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
WO2017039313A1
(en)
|
2015-09-01 |
2017-03-09 |
한양대학교 산학협력단 |
Antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf
|
CA3000462C
(en)
|
2015-10-05 |
2024-04-02 |
Salk Institute For Biological Studies |
Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
|
WO2017070110A1
(en)
|
2015-10-19 |
2017-04-27 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
US11246896B2
(en)
|
2015-10-28 |
2022-02-15 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Tumor-specific adenovirus vectors and therapeutic uses
|
EP3390428B1
(en)
|
2016-02-23 |
2019-09-25 |
Salk Institute for Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
KR102471633B1
(en)
|
2016-02-23 |
2022-11-25 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
JP7208492B2
(en)
|
2016-03-10 |
2023-01-19 |
シージー オンコロジー, インコーポレイテッド |
Methods of treating solid tumors or lymphoid tumors with combination therapy
|
US20170314044A1
(en)
|
2016-05-02 |
2017-11-02 |
Regents Of The University Of Minnesota |
Adenovirus constructs and methods
|
WO2017205423A1
(en)
|
2016-05-23 |
2017-11-30 |
Washington University |
Pulmonary targeted cas9/crispr for in vivo editing of disease genes
|
WO2017205875A1
(en)
|
2016-05-27 |
2017-11-30 |
Dnatrix, Inc. |
Adenovirus and immunomodulator combination therapy
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
FI20165814A
(en)
|
2016-10-27 |
2018-04-28 |
Tilt Biotherapeutics Oy |
INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY
|
US20190275092A1
(en)
|
2016-11-01 |
2019-09-12 |
Dnatrix, Inc. |
Combination therapy for treatment of brain cancers
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
WO2018083259A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
US20190350992A1
(en)
|
2016-11-17 |
2019-11-21 |
Vcn Biosciences Sl |
Use of viral vectors in the treatment of retinoblastoma
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
EP3551644B1
(en)
|
2016-12-09 |
2023-08-16 |
GlaxoSmithKline Biologicals SA |
Chimpanzee adenovirus constructs with lyssavirus antigens
|
AU2017375633C1
(en)
|
2016-12-12 |
2023-04-27 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
WO2018125970A1
(en)
|
2016-12-30 |
2018-07-05 |
Salk Institute For Biological Studies |
Synthetic adenoviruses targeting bone tissue and uses thereof
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
BR112019015514A2
(en)
|
2017-01-30 |
2020-04-07 |
Epicentrx Inc |
tumor-selective tata-box and caat-box mutants
|
EP3574090A4
(en)
|
2017-01-30 |
2021-01-06 |
EpicentRx, Inc. |
Multiple transgene recombinant adenovirus
|
EA201990822A1
(en)
|
2017-04-12 |
2020-01-09 |
Эписентарикс, Инк. |
IMMUNOMODULATING FUSION PROTEINS
|
JP7260173B2
(en)
|
2017-04-21 |
2023-04-18 |
ベイラー カレッジ オブ メディスン |
Oncolytic virus therapy and immunotherapy
|
WO2018201017A1
(en)
|
2017-04-27 |
2018-11-01 |
Washington University |
Dendritic cell targeted adenovirus for vaccination
|
WO2018204677A1
(en)
|
2017-05-04 |
2018-11-08 |
Epicentrx, Inc. |
Oncolytic adenovirus formulation
|
US20200155625A1
(en)
|
2017-05-24 |
2020-05-21 |
Epicentrx, Inc. |
Anti-angiogenic adenovirus
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
WO2019016756A1
(en)
|
2017-07-21 |
2019-01-24 |
Glaxosmithkline Biologicals Sa |
Chikungunya virus antigen constructs
|
PL3460052T3
(en)
|
2017-09-20 |
2020-05-18 |
Immunicum Ab |
Improved allogeneic dendritic cells for use in cancer treatment
|
WO2019073059A1
(en)
|
2017-10-12 |
2019-04-18 |
Freeline Therapeutics Limited |
Life-cycle-defective adenovirus helper viruses, their production and use for producing raav
|
MA50502A
(en)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention Bv |
ADENOVIRUS AND RELATED USES
|
MX2020004492A
(en)
|
2017-10-31 |
2020-11-24 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof.
|
CN111295391B
(en)
|
2017-10-31 |
2023-12-05 |
扬森疫苗与预防公司 |
Adenovirus and use thereof
|
CA3077630A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
GB201802539D0
(en)
|
2018-02-16 |
2018-04-04 |
Univ College Cardiff Consultants Ltd |
Modified adenoviruses
|
GB201804473D0
(en)
|
2018-03-21 |
2018-05-02 |
Valo Therapeutics Oy |
Modified oncolytic adenoviruses
|
GB201804468D0
(en)
|
2018-03-21 |
2018-05-02 |
Valo Therapeutics Oy |
PeptiCRAd Cancer Therapy
|
US20210015878A1
(en)
|
2018-03-28 |
2021-01-21 |
Epicentrx, Inc. |
Personalized cancer vaccines
|
EP3775175A4
(en)
|
2018-04-09 |
2022-02-09 |
Salk Institute for Biological Studies |
Oncolytic adenovirus compositions with enhanced replication properties
|
TW202011977A
(en)
|
2018-04-20 |
2020-04-01 |
貝勒醫學院 |
Oncolytic virotherapy and immunotherapy
|
JP2021526831A
(en)
|
2018-06-12 |
2021-10-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Adenovirus polynucleotides and polypeptides
|
WO2020014539A1
(en)
|
2018-07-11 |
2020-01-16 |
Epicentrx, Inc. |
Methods and compositions for targeting cancer cells for treatment
|
JP2022500013A
(en)
|
2018-08-31 |
2022-01-04 |
オルカ セラピューティクス ビー.ブイ. |
Methods for Killing Recombinant Viruses and Abnormal Cells Containing the Coding Region of Glycogen Synthase Kinase-3 (GSK3)
|
EP3864159A4
(en)
|
2018-10-09 |
2022-11-02 |
Nikegen Limited |
Compositions and methods for preparing viral vectors
|